US EditionPharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s continue rise
Summary by Drug Discovery and Development
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s continue rise
With the $30B Keytruda franchise leading, Oncology maintained its top position among the top 50 drugs in FY2024, but significant shifts occurred across therapeutic areas. Metabolic Diseases saw major growth, as GLP-1 agonists like Ozempic (+26%), Mounjaro (+124%), and Wegovy (+86%) reshaped the diabetes and obesity markets. Landmark trials from late 2023 to present also… The post Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s co…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage